CD22 and non-small cell lung carcinoma: It has been reported that CD22 functions as a regulator of B-cell response and is associated with oxaliplatin resistance in colon cancer, while ZNF114 potentially promotes non-small cell lung cancer (NSCLC) metastasis [56–58].